scholarly journals Subacute Cutaneous Lupus Erythematosus-Like Drug Eruption Related to Terbinafine in a Male

2021 ◽  
Vol 5 (4) ◽  
pp. 437-440
Author(s):  
Haley Danielle Heibel ◽  
Sidra Ibad ◽  
Parneet Dhaliwal ◽  
Sharif Currimbhoy ◽  
Clay J. Cockerell
Keyword(s):  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Connective Tissue Diseases ◽  
Vascular Diseases ◽  
Future Research ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
Collagen Vascular Diseases ◽  
History Of ◽  
Cutaneous Lupus

        Patients with a history of or a predisposition to autoimmune or collagen vascular diseases are inclined to develop drug-induced subacute cutaneous lupus erythematosus (SCLE) due to terbinafine therapy.  Here, we report a case of terbinafine-induced SCLE in a male patient, although classic SCLE most commonly affects females, and he did not have a diagnosis of or a history suggestive of a predisposition to autoimmune or collagen vascular diseases.  Although the mechanism for terbinafine-induced SCLE has not been fully elucidated, we suggest that there may be distinctive mechanisms of terbinafine-induced SCLE of patients with and without a predisposition to or history of autoimmune or connective tissue diseases, which should be a focus of future research.

scholarly journals Capecitabine-Induced Subacute Cutaneous Lupus Erythematosus in a Patient with Systemic Lupus Erythematosus

2018 ◽  
Vol 2 (1) ◽  
pp. 59-63
Author(s):  
Alyx Rosen ◽  
Evan Darwin ◽  
Jennifer N Choi
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Metastatic Breast ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Systemic Lupus ◽  
Drug Induced ◽  
Increased Risk ◽  
History Of ◽  
Cutaneous Lupus

Capecitabine is a fluoropyrimidine chemotherapy prodrug of 5-fluorouracil (5-FU) used in the treatment of metastatic breast and colorectal cancers. Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is a rare side effect of capecitabine therapy, with eight cases previously reported. We report a case of DI-SCLE in a patient with a documented history of systemic lupus erythematosus (SLE). This is the second documented case of DI-SCLE in a patient with a past medical history of SLE, and provides evidence that there may be an increased risk of DI-SCLE in these patients. Further research should examine whether patients with SLE are at greater risk for this adverse event. 

Drug-induced subacute cutaneous lupus erythematosus associated with abatacept

Lupus ◽  
2020 ◽  
pp. 096120332098114
Author(s):  
Eliana Figueredo Zamora ◽  
Jeffrey P Callen ◽  
Courtney R Schadt
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Time Course ◽  
Cutaneous Lupus Erythematosus ◽  
Clinical Findings ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
The Third ◽  
History Of ◽  
Cutaneous Lupus

Numerous drugs have been linked to the induction or exacerbation of systemic cutaneous lupus erythematosus (SCLE). This report presents the third case of the biologic abatacept as an exacerbating medication for SCLE. A 73-year old woman with a remote history of subacute cutaneous lupus and rheumatoid arthritis, well controlled on hydroxychloroquine, presented with worsening annular erythematous, slightly scaly plaques on her forearms and hands. She had been started on abatacept a month prior. She was diagnosed with SCLE exacerbated by abatacept given the clinical findings, time course, and skin biopsy with interface dermatitis. Her skin eruption cleared completely several months later after discontinuing abatacept and switching to tociluzumab, while remaining on hydroxychloroquine. This case highlights the need to consider abatacept as a potential exacerbating medication for SCLE in any patient with a new photodistributed papulosquamous eruption.

scholarly journals Drug-induced subacute cutaneous lupus erythematosus caused by amlodipine

2018 ◽  
Vol 105 (2) ◽  
pp. 298-306
Author(s):  
Agata Kozłowska ◽  
Zdzisław Woźniak ◽  
Joanna Maj ◽  
Rafał Białynicki-Birula
Keyword(s):  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
Cutaneous Lupus

scholarly journals Subacute cutaneous lupus erythematosus with a possible paraneoplastic association with melanoma

2019 ◽  
Vol 12 (11) ◽  
pp. e230558 ◽  
Author(s):  
Jesse Hirner
Keyword(s):  
Proton Pump Inhibitor ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Laboratory Evaluation ◽  
Topical Steroids ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
Dermatology Clinic ◽  
Common Causes ◽  
Cutaneous Lupus

A 52-year-old man was referred to our dermatology clinic for a diagnosis of melanoma. At the time, his melanoma was excised he developed an annular, polycyclic, scaling eruption consistent with subacute cutaneous lupus erythematosus (SCLE). Skin biopsy and laboratory evaluation confirmed this diagnosis. The patient had been using pantoprazole for gastro-oesophageal reflux disease for the last 3 years. The patient’s melanoma was treated surgically, and his SCLE was treated with topical steroids and hydroxychloroquine. His SCLE cleared rapidly, his steroids and hydroxychloroquine were stopped and he remains free of SCLE off of treatment. The parallel course of the patient’s SCLE and melanoma prompted consideration of SCLE as paraneoplastic to melanoma in this case. The clinical picture was complicated by the patient’s use of a proton pump inhibitor, which are common causes of drug-induced SCLE. To our knowledge, this is the first reported case of possible paraneoplastic SCLE associated with melanoma.

Sign in / Sign up

Export Citation Format

Share Document